Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated January 7, 2026, reports the announcement of positive results from two pivotal Phase III clinical trials (B-Well 1 and B-Well 2) for bepirovirsen. The trials evaluated this investigational antisense oligonucleotide (ASO) as a potential first-in-class treatment for chronic hepatitis B (CHB) across 29 countries involving over 1,800 patients.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical trial outcomes and regulatory strategy.
Material Changes and Clinical Results
- Primary Endpoint Achievement: Both B-Well 1 and B-Well 2 trials met their primary endpoints.
- Functional Cure Rates: Bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate compared to standard of care alone.
- Subgroup Performance: Results were statistically significant across all ranked endpoints, with an even greater effect observed in patients with baseline surface antigen (HBsAg) levels of 1000 IU/ml or less.
- Safety Profile: The trials demonstrated an acceptable safety and tolerability profile consistent with previous studies.
Guidance, Outlook, and Management Commentary
Management, including Chief Scientific Officer Tony Wood, stated that bepirovirsen has the potential to transform treatment goals for CHB by achieving significant functional cure rates, a first for the disease. The company plans to submit global regulatory filings starting in Q1 2026. If approved, bepirovirsen could become the first finite, six-month therapeutic option for CHB and serve as a backbone for future sequential treatment strategies. Full results are expected to be presented at an upcoming scientific congress and published in a peer-reviewed journal.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in GSK's 2024 Annual Report on Form 20-F and Q3 2025 results.
Key Facts for Investor Verification
- Confirmation of the specific functional cure rate percentages in the full clinical data release.
- Timeline and status of regulatory submissions planned for Q1 2026 in key markets (US, EU, China, Japan).
- Impact of this development on GSK's overall R&D pipeline valuation and potential revenue projections for the hepatology portfolio.
- Details on the collaboration agreement with Ionis Pharmaceuticals regarding licensing and royalty terms.